ArticleJournal of medical biochemistry2026
Serum levels of immunoglobulins, tumour markers, and chemokines in gastric cancer patients treated with SOX regimen versus oxaliplatin monotherapy.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer is a leading cause of cancer-related mortality, emphasising the need for reliable bio-markers for prognosis and treatment monitoring. This study evaluates serum levels of immunoglobulins (IgA, IgG, IgM), cancer markers (CA125, CEA), and other biomarkers (MRP-14, SDF-1, FSP-1, CXCR4) in gastric cancer patients after treatment. Methods: 100 gastric cancer patients were randomised into two treatment groups: oxaliplatin plus capecitabine (reference) and the SOX regimen (oxaliplatin plus S-1; observation). Serum biomarker levels were measured before and after treatment using flow cytometry and enzyme immunoassays. Clinical efficacy, immune response, and chemotherapy-related toxicity were analysed. Results: The SOX regimen demonstrated superior clinical efficacy, with higher objective response (76% vs. 62%) and disease control rates (94% vs. 86%) compared to oxaliplatin monotherapy. The SOX group exhibited significantly higher post-treatment levels of IgA, IgG, and IgM and increased CD 3+, CD 4+, and NK cell counts. Tumour marker levels (CA125, CEA, MRP-14, SDF-1, FSP-1, CXCR4) were lower in the SOX group, with fewer chemotherapy-related adverse effects. Conclusions: The SOX regimen enhances immune function, reduces tumour markers, and improves treatment outcomes compared to oxaliplatin monotherapy. Serum bio-markers may be valuable for monitoring therapeutic responses in gastric cancer patients. However, the study's small sample size and retrospective design limit the generalizability of the findings. Further studies are necessary to confirm these results and validate the prognostic value of serum biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.